Table 2.

The use of organoids for alternative and targeted therapy sensitivity testing in TNBC.

Therapeutic Agents	Dose Ranges/IC50 Values	Main Results	References
ACY1215	6.7 μM	Tektin4-deficient organoids favor the efficacy of HDAC6 inhibitors	[40]
Apigenin	1–50 μM	Organoid growth reduction	[49]
BAPN	25 mM	BAPN-Doxorubicin synergy leads to organoid shrinkage	[48]
Birinapant		50% of the employed TNBC patient-derived xenograft organoid lines showed remarkable sensitivity to birinapant	[41]
Bromodomain inhibitor, Extra-terminal protein inhibitor		Correlation with MARCO-TST expression	[52]
CFI-400945	1–50 nM	Synergy of radiation therapy and CFI-400945	[47]
EPZ-5676	10 nmol/L	Organoid growth reduction	[43]
Eribulin		Patient-derived xenograft organoid pharmaco-phenotyping predicates patient-specific sensitivities for personalized therapy	[41]
FMF-04-159-2		Organoid growth reduction, Cell proliferation inhibition, Apoptosis induction	[53]
GR inhibitor, STAT3 inhibitor	0.1–8 μM, 1–11 μM	Significant, synergistic, dose-dependent decrease in TNBC cell growth	[39]
LFS-1107	189.8 nM–1.187 μM	Organoid growth inhibition	[46]
MS023	0–10 μM	Correlation with basal interferon gene expression Upregulation of T1-helper cell chemokines and antigen presentation genes	[50]
Nicotinamide	IC50 values = 12–30 mM	Organoid growth reduction	[42]
PF-543, Fingolimod	10 μM, 1 μM	Higher efficacy in LAR positive TNBC	[51]
RU.521, Afatinib, Gefitinib	20 μM, 10 μM, 10 μM	Synergistic inhibitory effects on organoid growth	[45]